Bluebird bio CMO quits amid a roller coaster year and upcoming split | Fierce Biotech
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
BLUE stock on watch as Morgan Stanley predicts regulatory win (NASDAQ:BLUE) | Seeking Alpha
Mergers & Acquisitions - bluebird bio
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
Why Bluebird Bio Stock Stumbled Today | The Motley Fool
Why Bluebird Bio Stock Is Sinking This Week | The Motley Fool
bluebird bio Inc., Undervalued Acquisition Candidate (NASDAQ:BLUE) | Seeking Alpha
Acceleron To Be Next M&A Target With Rumored $11bn Deal :: Scrip
Could This Beaten-Down Biotech Stock Be the Next Buyout Target? | The Motley Fool
JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches | Fierce Pharma
Why Bluebird Bio Stock Is Taking Flight Today | The Motley Fool
Monday's Top Analyst Upgrades and Downgrades: Applied Materials, BJ's Wholesale, Bluebird Bio, eBay, Foot Locker, Kohl's, Salesforce, Snowflake and More – 24/7 Wall St.
Will Bluebird Bio's Big Gamble Payoff? | Biotech Investing | Sick Economics
bluebird bio: A Speculative Buy With Extraordinary Upside Potential (BLUE) | Seeking Alpha
bluebird bio: Returning To A Previous Winner (NASDAQ:BLUE) | Seeking Alpha
Bluebird Bio sees Europe as first market for its gene therapies | Fierce Biotech
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
StockWatch: After Bluebird's Second Approval, Investors Are Looking for More
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
AavantiBio snags another bluebird bio VP with gene therapy chops as 6th executive hire this year | Fierce Biotech
Pfizer Is in Talks to Buy Sickle-Cell Drugmaker, WSJ Reports - Bloomberg
Eric Hacherl (@EricHacherl) / Twitter
Xconomy: Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More
